Regulus Therapeutics (RGLS) Stock | Here’s What You Need To Know

Regulus Therapeutics (NASDAQ:RGLS) In after-hours trade on Monday June 27, 2016 shares of Regulus Therapeutics tanked as much as 60% after the company announced that the FDA had placed their Hepatitis C drug on a clinical hold. It is not a good thing that the company’s drug, RG-101 has been placed on a clinical hold. … Read more

Biotech Stock News (AMGN) (RGLS) (BIIB) (RVNC) (AGN)

Amgen, Inc. (NASDAQ:AMGN) On October 28, 2015 Amgen had announced that it had received FDA approval for its skin cancer drug known as IMLYGIC. This drug is an injection type drug that helps boost the immune system to fight off and kill cancerous skin cells. This therapy only treats Melanoma — skin cancer– but does … Read more

Biotech Stock News (IMGN) (RGLS) (GILD) (ACHN) (OPK) (BRLI)

Immunogen (NASDAQ:IMGN) Shares of Immunogen soared as much as 68% on June 1, 2015 after the company reported positive results in patients with platinum-resistant ovarian cancer. There are about 21,290 cases of women who get ovarian cancer in the United States each year. The problem is that a lot of these patients that take chemotherapy … Read more

Biotech Stock News (RGLS)(AZN)(INO)(TKMR)

Regulus Therapeutics (NASDAQ:RGLS) & AstraZeneca (NYSE:AZN)¬† On April 7, 2015 Shares of Regulus were up about 8% in after hours trading after the company reported that Astrazeneca would like to collaborate with the company to develop a NASH drug. NASH stands for non-alcoholic steatohepatitis and as the name suggests it is a disease that doesn’t … Read more

Biotech News- 2/9/15 to 2/13/15

Achillion Pharmaceuticals (ACHN) Shares of Achillion gained 7% on 2/9/15 last week when it had¬†announced that it had achieved a 100% SVR12 in a phase 2 trial treating patients with the genotype 1 version of the Hepatitis C virus — HCV. The trial tested for the primary objective of patients being able to achieve a … Read more